Xilio Therapeutics Inc. (XLO) NASDAQ
$1.16 (0.12) (-9.38%)
Market Cap: $44.13M
As of 04/19/24 03:44 PM EDT. Market closed.
Xilio Therapeutics Inc. (XLO)
NASDAQ
$1.16
(0.12) (-9.38%)
Market Cap: $44.13M
As of 04/19/24 03:44 PM EDT. Market closed.
xilio is a waltham, massachusetts-based biopharmaceutical company focused on defeating cancer. the company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, xilio, derived from the latin term, ex nihilo, meaning creation or big-bang. xilio is applying its technology to ... read more
xilio is a waltham, massachusetts-based biopharmaceutical company focused on defeating cancer. the company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, xilio, derived from the latin term, ex nihilo, meaning creation or big-bang. xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. to learn more, please visit www.xiliotx.com. read less
Open in: 
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| GILEAD SCIENCES, INC. | 10% Owner | Apr 02, 2024 | Buy | $0.76 | 485,250 | 368,790 | 7,345,473 | Apr 03, 2024, 06:50 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 08, 2024 | Sale | $0.64 | 733 | 469 | 2,019,563 | Feb 09, 2024, 04:33 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 08, 2024 | Sale | $0.64 | 267 | 171 | 734,546 | Feb 09, 2024, 04:33 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Jan 12, 2024 | Sale | $0.83 | 560 | 465 | 734,813 | Jan 16, 2024, 06:16 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Jan 12, 2024 | Sale | $0.83 | 1,540 | 1,278 | 2,020,296 | Jan 16, 2024, 06:16 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Jan 11, 2024 | Sale | $0.87 | 569 | 495 | 735,373 | Jan 16, 2024, 06:16 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Jan 11, 2024 | Sale | $0.87 | 1,566 | 1,362 | 2,021,836 | Jan 16, 2024, 06:16 PM |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 08, 2021 | Buy | $9.62 | 13,458 | 129,474 | 2,776,402 | Dec 10, 2021, 08:33 PM |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 10, 2021 | Buy | $9.65 | 25,000 | 241,202 | 2,805,413 | Dec 10, 2021, 08:33 PM |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 09, 2021 | Buy | $9.84 | 4,011 | 39,485 | 2,780,413 | Dec 10, 2021, 08:33 PM |
| SV7 Impact Medicine Fund LP | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 312,500 | 5,000,000 | 1,613,632 | Nov 03, 2021, 04:20 PM |
| SV7 Impact Medicine Fund LP | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 312,500 | 5,000,000 | 1,613,632 | Nov 03, 2021, 04:20 PM |
| Flynn James E | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 387,500 | 6,200,000 | 1,143,972 | Oct 28, 2021, 07:15 PM |
| Flynn James E | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 387,500 | 6,200,000 | 1,143,972 | Oct 28, 2021, 07:15 PM |
| RiverVest Venture Fund IV, L.P. | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 250,000 | 4,000,000 | 1,441,444 | Oct 26, 2021, 05:30 PM |
| Rock Springs Capital Management LP | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 500,000 | 8,000,000 | 1,256,472 | Oct 26, 2021, 05:04 PM |
| BAY CITY CAPITAL LLC | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 312,500 | 5,000,000 | 1,129,490 | Oct 26, 2021, 05:02 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 187,500 | 3,000,000 | 735,942 | Oct 26, 2021, 05:01 PM |
| Owner | Relationship | Date | Value($) |
| GILEAD SCIENCES, INC. | 10% Owner | 04/02/2024 | 368,790 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/08/2024 | 469 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/08/2024 | 171 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 01/12/2024 | 465 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 01/12/2024 | 1,278 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 01/11/2024 | 495 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 01/11/2024 | 1,362 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 12/08/2021 | 129,474 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 12/10/2021 | 241,202 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 12/09/2021 | 39,485 |
| SV7 Impact Medicine Fund LP | 10% Owner | 10/26/2021 | 5,000,000 |
| SV7 Impact Medicine Fund LP | 10% Owner | 10/26/2021 | 5,000,000 |
| Flynn James E | 10% Owner | 10/26/2021 | 6,200,000 |
| Flynn James E | 10% Owner | 10/26/2021 | 6,200,000 |
| RiverVest Venture Fund IV, L.P. | 10% Owner | 10/26/2021 | 4,000,000 |
| Rock Springs Capital Management LP | 10% Owner | 10/26/2021 | 8,000,000 |
| BAY CITY CAPITAL LLC | 10% Owner | 10/26/2021 | 5,000,000 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 10/26/2021 | 3,000,000 |
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 209,700 | 0.00018% | 913.04% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 84,826 | 0% | No change | Other |
| BLACKROCK INC. | 46,862 | 0% | -1.1% | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View